poisar

Stocks · News reference

TD Cowen Maintains Buy on Biote, Lowers Price Target to $2

BenzingaBenzinga Newsdesk

TD Cowen analyst Jonna Kim maintains Biote (NASDAQ:BTMD) with a Buy and lowers the price target from $2.5 to $2.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolThe Motley Fool Team

    biote: 3 Key Takeaways for Long-Term Investors

    biote reported Q3 2026 results with a 9.6% year-over-year revenue decline to $43.3 million, attributed to a January 2026 product recall that delayed clinic onboarding. Despite this, the company maintains full-year 2026 revenue guidance above $175 million. Management is deploying data analytics to support underperforming clinics, standardizing medical training to retain practitioners, and ramping up internal manufacturing at Xteria Health to restore gross margins, with early signs of procedure volume stabilization.

  2. SEC EDGARSEC EDGAR

    8-K filing — biote Corp. (BTMD)

    Filed: 2026-11-04 AccNo: 0001193125-26-447331 Size: 911 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits